IBIO – Ibio Inc

Not Compliant

The company’s impure earnings are more than 5% of its total revenues.

Pharmaceuticals
NYSE MKT

iBio, Inc. is a developer of next-generation biopharmaceuticals using its proprietary artificial intelligence (AI)-Driven Discovery Platform and FastPharming Manufacturing System. The Company is focusing its technologies on the research and development of novel products at its Drug Discovery Center in California. The Company through its FastPharming Manufacturing System and GlycaneeringSM Technologies develop its portfolio of proprietary biologic drug candidates. The Company operates through two segments: Biopharmaceuticals, and Bioprocessing. Its Biopharmaceuticals segment is engaged in large molecule discovery, development, and licensing activities. Its Bioprocessing segment is engaged in contract development and manufacturing services for recombinant proteins. Its pipeline includes IBIO-100, IBIO-101, IBIO-202, and IBIO-400. Its subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with GlycaneeringSM Development Services.

AAOIFI ✗

Debt ÷ Market cap (MC)

171.22

✗

Non-Compliant Assets ÷ MC

96.06

✗

Impure Income (incl. Interest)

7.47

✗

Impure Income	%
Interest Income	7.47%
Total	7.47%

Found the Stock You’re Looking For? Open an Account Today!

Opening an account has never been easier! Please fill out the form here and an advisor will be in touch to walk you through the process!

Still have some further questions?